收费全文 | 740203篇 |
免费 | 55955篇 |
国内免费 | 1672篇 |
耳鼻咽喉 | 10774篇 |
儿科学 | 20936篇 |
妇产科学 | 21167篇 |
基础医学 | 105013篇 |
口腔科学 | 21575篇 |
临床医学 | 65073篇 |
内科学 | 142284篇 |
皮肤病学 | 14215篇 |
神经病学 | 59878篇 |
特种医学 | 29531篇 |
外国民族医学 | 142篇 |
外科学 | 115755篇 |
综合类 | 20459篇 |
现状与发展 | 3篇 |
一般理论 | 288篇 |
预防医学 | 57425篇 |
眼科学 | 17684篇 |
药学 | 54976篇 |
14篇 | |
中国医学 | 1389篇 |
肿瘤学 | 39249篇 |
2018年 | 6826篇 |
2015年 | 7029篇 |
2014年 | 10217篇 |
2013年 | 15523篇 |
2012年 | 20884篇 |
2011年 | 21944篇 |
2010年 | 12957篇 |
2009年 | 12042篇 |
2008年 | 20864篇 |
2007年 | 22673篇 |
2006年 | 22448篇 |
2005年 | 22252篇 |
2004年 | 21660篇 |
2003年 | 20800篇 |
2002年 | 19937篇 |
2001年 | 29084篇 |
2000年 | 29633篇 |
1999年 | 25236篇 |
1998年 | 7950篇 |
1997年 | 7282篇 |
1996年 | 7161篇 |
1995年 | 6756篇 |
1994年 | 6531篇 |
1992年 | 21696篇 |
1991年 | 21284篇 |
1990年 | 20785篇 |
1989年 | 20126篇 |
1988年 | 18788篇 |
1987年 | 18482篇 |
1986年 | 17600篇 |
1985年 | 17093篇 |
1984年 | 13400篇 |
1983年 | 11532篇 |
1982年 | 7525篇 |
1981年 | 6824篇 |
1980年 | 6484篇 |
1979年 | 13696篇 |
1978年 | 9859篇 |
1977年 | 8385篇 |
1976年 | 7629篇 |
1975年 | 8310篇 |
1974年 | 10279篇 |
1973年 | 9886篇 |
1972年 | 9378篇 |
1971年 | 8630篇 |
1970年 | 8287篇 |
1969年 | 7968篇 |
1968年 | 7185篇 |
1967年 | 6687篇 |
1966年 | 6160篇 |
- Download : Download high-res image (451KB)
- Download : Download full-size image
To determine frequencies, interlaboratory reproducibility, clinical ratings, and prognostic implications of neural antibodies in a routine laboratory setting in patients with suspected neuropsychiatric autoimmune conditions.
MethodsEarliest available samples from 10,919 patients were tested for a broad panel of neural antibodies. Sera that reacted with leucine-rich glioma-inactivated protein 1 (LGI1), contactin-associated protein-2 (CASPR2), or the voltage-gated potassium channel (VGKC) complex were retested for LGI1 and CASPR2 antibodies by another laboratory. Physicians in charge of patients with positive antibody results retrospectively reported on clinical, treatment, and outcome parameters.
ResultsPositive results were obtained for 576 patients (5.3%). Median disease duration was 6 months (interquartile range 0.6–46 months). In most patients, antibodies were detected both in CSF and serum. However, in 16 (28%) patients with N-methyl-d-aspartate receptor (NMDAR) antibodies, this diagnosis could be made only in cerebrospinal fluid (CSF). The two laboratories agreed largely on LGI1 and CASPR2 antibody diagnoses (κ = 0.95). The clinicians (413 responses, 71.7%) rated two-thirds of the antibody-positive patients as autoimmune. Antibodies against the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), NMDAR (CSF or high serum titer), γ-aminobutyric acid-B receptor (GABABR), and LGI1 had ≥ 90% positive ratings, whereas antibodies against the glycine receptor, VGKC complex, or otherwise unspecified neuropil had ≤ 40% positive ratings. Of the patients with surface antibodies, 64% improved after ≥ 3 months, mostly with ≥ 1 immunotherapy intervention.
ConclusionsThis novel approach starting from routine diagnostics in a dedicated laboratory provides reliable and useful results with therapeutic implications. Counseling should consider clinical presentation, demographic features, and antibody titers of the individual patient.
相似文献Introduction
There is an urgent need for new anti-tuberculosis (TB) drugs and optimization of current TB treatment. Moxifloxacin and linezolid are valuable options for the treatment of drug-resistant TB; however, it is crucial to find a dose at which these drugs not only show high efficacy but also suppress the development of further drug resistance.Methods
Activity of moxifloxacin and linezolid against Mycobacterium tuberculosis was studied in the hollow-fiber infection model system in log-phase growth under neutral pH and slow growth in an acidic environment. Doses that achieved maximum bacterial kill while suppressing the emergence of drug resistance were determined. Through Monte Carlo simulations the quantitative output of this in vitro study was bridged to the human patient population to inform optimal dosage regimens while accounting for clinical minimum inhibitory concentration (MIC) distributions.Results and Discussion
Moxifloxacin activity was significantly decreased in an acidified environment. The loss of activity was compensated by accumulation of the drug in TB lung lesions; therefore, moderate efficacy can be expected. Moxifloxacin 800 mg/day is the dose that most likely leads to resistance suppression while exerting maximum bacterial kill. Linezolid demonstrated very good activity even at a reduced pH. Linezolid 900 mg once-daily (QD) is likely to achieve a maximum killing effect and prevent the emergence of drug resistance; 600 mg QD in a robust drug regimen may have similar potential. 相似文献- Download : Download high-res image (134KB)
- Download : Download full-size image